Letrozole Superior to Tamoxifen For Treatment of Advanced Breast Cancer
J Clin Oncol 2001;19:2596-2606.
WESTPORT, CT (Reuters Health)- Letrozole is significantly more efficacious
than tamoxifen as first-line endocrine therapy for postmenopausal women
with advanced breast cancer, according to a multinational research team.
The investigators describe the study as the single largest to date that has
been conducted with an aromatase inhibitor as first-line endocrine
treatment of advanced breast cancer.
Dr. Hilary A. Chaudri-Ross, of Novartis Pharma AG in Basel, Switzerland,
and colleagues treated patients from 201 centers in 29 countries who had
stage IIIB breast cancer, or loco-regionally recurrent disease not amenable
to surgery or radiation therapy, or metastatic disease. Therapy with
letrozole 2.5 mg/day was randomly assigned to 453 patients and tamoxifen 20
mg/day to 454 patients.
As described in the Journal of Clinical Oncology for May 15, tumors were
estrogen receptor- and/or progesterone receptor-positive, or else the
status of both receptors was unknown. Some patients had had one regimen of
Letrozole reduced the risk of progression by 30% compared with tamoxifen.
Median time to progression was 41 weeks for letrozole and 26 weeks for
tamoxifen. Letrozole was also significantly superior in time to treatment
failure, objective response rate, and rate of clinical benefit.
The investigators note that the results were maintained after adjustment
for receptor status, prior adjuvant antiestrogen therapy, and dominant site
of disease. Adverse events were similar in nature and frequency for the two
|Remember we are NOT Doctors and have NO medical training.|
This site is like an Encyclopedia - there are many pages, many links on many topics.
Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.